John Slump CEO & Co-founder

Coming soon.

Therapeutic: Coming soon.

Ilan Uchitel Co-Founder & CEO

CAPS Medical (Israel) has developed a proprietary PlasmaSure technology that uses Non Thermal Plasma (NTAP) to selectively target tumors through minimally invasive procedures. The PlasmaSure system uses existing minimally invasive tools and robotic systems, targeting a $100B TAM. CAPS effectively eliminates cancerous cells while preserving healthy tissue, allowing treatments to move from the operating room into a doctor's clinic. The technology is clinically tested and applicable to wide range of tumors.

Therapeutic: Oncology

Evan Luxon CEO

Centese (Omaha, NE, USA) has developed Thoraguard, a digital medical device that transforms the recovery process for patients undergoing cardiothoracic surgery. The device is 510(k) cleared, has been used in over 5,000 patients, and has strong clinical evidence demonstrating a 1-day reduction in length of stay in thoracic surgery and 30% reduction in the rate of post-op AFib in cardiac surgery. Thoraguard’s initial users include some of the top cardiothoracic surgeons in the world, who have enthusiastically endorsed the system.

Therapeutic: Thoracic Surgery, Cardiac Surgery

Anthony DePasqua Co-Founder & CEO

EnClear Therapies, Inc. (Cambridge, MA, USA) incorporated in Delaware, 2018 as a spin out of QurAlis, Inc. a biotechnology company working in the ALS space. EnClear was founded to overcome challenges in safely accessing the central nervous system to improve therapeutic options for neurodegenerative and neuro oncologic diseases. EnClear is developing the EnTrega CSF management platform. The EnTrega Platform’s primary goal is to increase the bioavailability of therapies within the central nervous system to improve therapeutic effect. In pre-clinical models, The EnTrega platform has been shown to increase tissue distribution of therapies, by as much as 1,000X when compared to standard of care. Combining safe, repeatable access to CSF with next generation sensing and CSF control, the EnTrega Platform improves therapeutic effect and decreases off target toxicity by increasing the distribution of therapies to where they are most effective. While providing real-time patient feedback and repeatable, automated CSF sampling for diagnostics.

Therapeutic: Drug Delivery; Neurology

Jay Cormier President & CEO

Eyedaptic (Laguna Hills, CA, USA) is pioneering the use of Augmented Reality (AR), powered by Artificial Intelligence (AI), to address the large unmet eye care need of Retinal Diseases, such as Macular Degeneration, afflicting over 200 million people worldwide. Effectiveness has been demonstrated, leading to strong user adoption and traction. These ultralight smart glasses adapt not only to the user’s vision but also their habits and environment, thereby empowering users to maintain their independence and quality of life across the widest range of tasks.

Therapeutic: Ophthalmology; Augmented Reality, Artificial Intelligence, Digital Health

Myles Greenberg Co-Founder & Exec Chair

Coming soon.

Therapeutic: Coming soon.

Leo Smit CEO

Revolutionizing cartilage recovery: Hy2Care’s (Geleen, Limburg, the Netherlands) CartRevive™ hydrogel implant realizes optimal regeneration of cartilage defects. After sports mishaps, slips, or falls, our patented hydrogel offers a scaffold of joint-matching composition, guiding natural cell growth and enabling the body to heal itself. Currently under clinical examination in the Netherlands for EU approval, with US trials coming up. Dive into the future of joint repair with us!

Therapeutic: Orthopedics-Spine; Regenerative Medicine

Jake Edick CEO

Magsorbeo Biomedical (Detroit, MI, USA) is a preclinical stage medical device development and manufacturing company founded by a team of industry veterans specializing in bioabsorbable metal implants. These fully absorbable implants are built from the patent pending and Magsorbeo owned Curasorb alloy to revolutionize treatment, improve outcomes, and reduce healthcare costs by eliminating removal procedures and life-threatening complications such as infections by absorbing and restoring tissue to its natural physiology, while maintaining performance of titanium implants.

Therapeutic: Biomaterials; Surgery

Stuart Mitchell Founder & CEO

Novuson (Bothell, WA, USA) is clearing the way for safer surgeries by eliminating excessive tissue damage and the associated smoke that obscures the surgeons field of view. Novuson developed the world's first Direct Therapeutic Ultrasound (DTU) surgical instruments for minimally invasive, robotic, and other surgical specialties. DTU is an alternative surgical energy modality that doesn't burn or char tissue and is more efficient than current technologies, making surgeries more precise, without risking the health and safety of the patients or the healthcare workers. Eliminating surgical smoke reduces health risks and potentially minimizes related complications. Novuson is positioned to commercialize their first devices pending FDA clearance and has $500k pre-commercialization revenue through a surgical robotics collaboration. They have 16 issued and pending US and International patents. Novuson’s vision is to improve surgical safety and patient outcomes, ultimately reducing healthcare costs.

Therapeutic: Minimally Invasive Surgery; Robotic Surgery

Chris Thatcher President & CEO

Coming soon.

Therapeutic: Coming soon.

Chris Darland CEO

Peerbridge Health (Nashville, TN, USA) is pioneering the next generation of AI-enabled wearable technology to solve the affordability and accessibility issues facing the US Health System. By combining best-in-class ECG signal fidelity with physics-based, explainable AI, the Cor device can deliver hospital grade diagnostics (Heart Failure, Obstructive Sleep Apnea) and monitoring (Ejection Fraction, Cardiac Output, 12 lead ECG) with much more to come.

Therapeutic: Cardiovascular; Diagnostics

Ram Ben-Yehuda Co-Founder/CEO

PhotoPill Medical (Rehovot/Israel) has a personalized electronic capsule for gut microbiota manipulation. First indication being Inflammatory Bowel Diseases (IBD), using autonomous navigation and Photobiomodulation treatments (PBMt), for non-invasive, effective, side-effect free therapy directly at the site of inflammation.

Therapeutic: Gastroenterology; Microbiota

Mark Nelson President & CEO

Precision Epigenomics (Tucson, AZ) is a molecular diagnostics company in the cancer detection space. Precision Epigenomics features liquid biopsy technology for early cancer detection.  We have created EPISEEK multi cancer detection test which can detect over 20 different cancers from a single blood draw. 

Therapeutic: Coming soon.

James Lancaster CEO

Coming soon.

Therapeutic: Coming soon.

Jeff Cambra CEO

SpinaFX (Vaughan, ON, Canada) is a medical treatment solution company providing rapid and sustained relief to patients with back pain due to contained lumbar herniated discs, using innovative, minimally invasive image-guided therapy.

Therapeutic: Pain management; Minimally Invasive Image-Guided Therapy

Justin Zenanko CEO & Co-founder

The patented SynerFuse™ (Eden Prairie, Minnesota, USA) procedure, Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™), combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery. The aims of SynerFuse is to decrease number of back fusions/surgeries related to pain and address chronic pain at the point of surgery.

Therapeutic: Neuromodulation-Neurostimulation; Spinal Fusion

Westbrook Weaver Founder & CEO

Coming soon.

Therapeutic: Coming soon.

Jeff Amacker CEO

TibaRay (Fremont, CA, USA) has novel technology that will treat cancer tumors with radiation over 400x faster than current treatments and reduce or eliminate collateral damage from the radiation. It is the first true disruption in the industry in decades and could become the new standard of care for 60% of cancer patients. Its core technology, which is well-patented, provides radiation from a micro-linear accelerator licensed from the Stanford Linear Accelerator Center (SLAC).

Therapeutic: Oncology

Martin Cook CEO

Company description

VenstraMedical (Newcastle, Australia and Minneapolis, MN, USA) has developed the smallest and most powerful next-generation temporary cardiac assist device, a percutaneous catheter-based pump (pVAD) protected by 7 issued patents, that allows for the device to be collapsed into a low-profile 9Fr catheter for insertion. Once expanded across the aortic valve the device provides full cardiac support, to over 7L/min, for cardiogenic shock patients and patients undergoing high risk coronary interventions.  We are looking to raise our Series B round to fund clinical trials with strong strategic and institutional interest.

Technology description

Our novel pVAD technology is the most powerful and smallest pVAD technology that we know, able to provide over 7L/min at physiological pressures and provide total left ventricular support for cardiogenic shock and other critically ill patients. Total support has been shown to reduce infarct size for heart attack patients and the recent DanGer shock trial has validated the use of pVAD technology in cardiogenic shock patients. The technology is based on 7 granted patents and no catheter or sheath larger than 9Fr is used in the percutaneous, cath lab, implant procedure. 

Therapeutic: Coming soon.

Jeremy Stueven CEO

Vitazi.ai (Santa Fe, NM, USA) provides a complete solution for diabetic retinopathy screening, eliminating the need for dilation and specialized training. Our VitaziView™ camera and VitaziCapture™ desktop application connect to OcuIoInsights™—our platform integrating retinal image capture, teleretinal services, AI insights, and a medical image database. While awaiting FDA 510K clearance for AI use, Vitazi.ai offers a teleretinal service with ophthalmologists reading scans via the Vitazi Image Grading Portal. The platform integrates with most EHR systems, delivering a comprehensive solution for clinicians and diagnostic centers.

Therapeutic: Artificial Intelligence; Telemedicine